Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

737.83 +2.64 (+0.36%)
Official Closing Price Updated: 7:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
 
Via Benzinga
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs. 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
Looking Into Eli Lilly's Recent Short Interest
 
Via Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases. 
Via Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Market Monitor February 6th
Market Recap: Wall Street Gains, Amazon Slips, and U.S. Job Growth Slows 
Via Chartmill
A Closer Look at Eli Lilly's Options Market Dynamics
 
Via Benzinga
Why Eli Lilly Stock Popped on Thursday
Via The Motley Fool
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
How To Ride The Market’s “Great Risk Rollercoaster”
This market is trading in an extremely tight range and has been for a long time now. It’s a market desperate for a catalyst just isn’t finding any - not in data, not in news, not in Tweets. 
Via Talk Markets
Topics ETFs Stocks / Equities
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
Wall Street cautious on mixed earnings, macroeconomic data, and geopolitical developments. Gold hits record high while Ford's outlook disappoints.Wall St cautious due to mixed earnings, data &... 
Via Benzinga
Topics Economy
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
LLY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence Economy Government
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
The 9 Best Stocks to Buy Now in February (2025)
Via The Motley Fool
In 2025, the pharmaceutical industry is ripe for M&A
Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment for mergers and acquisitions 
Via Equities.com
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches. 
Via Benzinga
Eli Lilly’s Q4 2024 Revenue Surges By 45% To $13.53 Billion
Eli Lilly and Company reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.